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Abstract 19 
Recent case-control genetic studies of attention deficit hyperactivity disorder (ADHD) have 20 
implicated common and rare genetic risk alleles, highlighting the polygenic and complex 21 
aetiology of this neurodevelopmental disorder. Studies of other neurodevelopmental disorders, 22 
such as autism spectrum disorder (ASD), Tourette disorder, developmental delay/intellectual 23 
disability, and schizophrenia indicate that identification of specific risk alleles and additional 24 
insights into disorder biology can be gained by studying non-inherited de novo variation. In 25 
this study, we aimed to identify large de novo copy number variants (CNVs) in children with 26 
ADHD. Children with a confirmed diagnosis of ADHD and their parents were genotyped and 27 
included in this sample. We used PennCNV to call large (>200kb) CNVs and identified those 28 
calls that were present in the proband and absent in both biological parents. In 305 parent-29 
offspring trios, we detected 14 de novo CNVs in 13 probands, giving a mutation rate of 4.6% 30 
and a per individual rate of 4.3%. This rate is higher than published reports in controls and 31 
similar to those observed for ASD, schizophrenia and Tourette disorder. We also identified de 32 
novo mutations at 4 genomic loci (15q13.1-13.2 duplication, 16p13.11 duplication, 16p12.2 33 
deletion and 22q11.21 duplication) that have previously been implicated in other 34 
neurodevelopmental disorders, two of which (16p13.11 and 22q11.21) have also been 35 
implicated in case-control ADHD studies. Our study complements ADHD case-control 36 
genomic analyses and demonstrates the need for larger parent-offspring trio genetic studies to 37 
gain further insights into the complex aetiology of ADHD.  38 
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Introduction 39 
Attention deficit hyperactivity disorder (ADHD) is a highly heritable (~70%), common and 40 
impairing neurodevelopmental disorder with a complex genetic architecture1. Recent case-41 
control genome-wide studies point to the involvement of thousands of relatively common 42 
single nucleotide polymorphisms (SNPs)2, very rare protein-truncating sequence variants and 43 
likely pathogenic missense mutations3, as well as large, rare copy number variants (CNVs)4–6. 44 
Although all of these classes of variant are associated with ADHD risk, robustly implicating 45 
specific risk alleles is an ongoing process. For instance, only a handful of CNV loci (e.g. 46 
15q13.3)5 have been individually implicated in risk of ADHD and given the large size of these 47 
loci, the specific genes involved are yet to be pinpointed. Studies of de novo mutations using 48 
parent-offspring trios provide an especially powerful approach to gene discovery because the 49 
background rate in unaffected individuals is low, and therefore if an elevated rate in cases is 50 
demonstrable, such mutations are likely pathogenic and can provide important insights into 51 
disease biology7.  52 
De novo likely-damaging mutations, that include CNVs which intersect genes, have been 53 
identified for other neurodevelopmental disorders, such as autism spectrum disorder (ASD), 54 
Tourette disorder, developmental delay/intellectual disability (DD/ID), and schizophrenia7–12. 55 
Individuals with ASD have a rate of de novo CNVs that is between 3- and 5-fold higher than 56 
in unaffected siblings or control individuals13. Individuals with simplex Tourette disorder have 57 
a similar rate of de novo CNVs to probands with ASD14 as do individuals with schizophrenia7. 58 
Of these neurodevelopmental disorders, the rate of de novo CNVs is highest in individuals with 59 
DD/ID, at approximately 10%15. 60 
Trio-based genetic studies of ADHD are lacking. There has been only one small study and it 61 
reported a rate of de novo CNVs (1.7% or 3 probands out of N=173) that was only slightly 62 
elevated above previous reports of de novo rates in controls16. In this study, we set out to 63 
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characterise large de novo CNVs in parent-offspring trios of probands diagnosed clinically with 64 
ADHD. 65 
Method 66 
Sample 67 
Children with ADHD, aged 5 to 17 years old, were recruited from UK child and adolescent 68 
mental health and paediatric clinics. ADHD diagnoses based on DSM-IV or DSM-III-R were 69 
confirmed via a semi-structured research diagnostic interview (the Child and Adolescent 70 
Psychiatric Assessment17) by trained, supervised psychologists. Full-scale IQ was assessed 71 
using the WISC-IV18. A proportion of the probands in the sample (N=136 or 44.6%) have been 72 
analysed in previous case-control CNV studies4,5. Approval for the study was obtained from 73 
the North West England and Wales Multicentre Research Ethics Committees. Written informed 74 
consent to participate was obtained from parents and children aged 16 years and older and 75 
assent was gained from children under 16 years of age. 76 
Genotyping, CNV calling and quality control (QC) 77 
DNA was obtained from blood and Oragene (saliva) samples for ADHD probands and both 78 
biological parents. N=424 ADHD parent-offspring trios were genotyped using a custom 79 
version of the Illumina PsychChip. Only samples with >95% call rate and those that passed a 80 
sex check were retained. Only complete trios that passed QC and an additional Mendel check 81 
in PLINK (to confirm biological relatedness) were used for CNV calling.  82 
CNVs were called using PennCNV19 and nearby calls were merged if the CNVs were separated 83 
by less than 50% of their combined length. CNVs were removed if they were called using <10 84 
probes, had size <50kb, probe density <20kb/probe or a PennCNV confidence score<10. 85 
Samples were removed if they had log R ratio standard deviation (LRR-SD)>0.3, B allele 86 
frequency (BAF)-drift>0.01 or waviness factor (WF)>0.05. Additionally, we applied further, 87 
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more stringent criteria in ADHD probands and excluded individuals with extreme scores on 88 
QC metrics (>4SD than the sample mean) as follows: if they had an apparently excessive CNV 89 
load (number of segments (NSEG)>50.8 or length in kilobases (KB)>16593) or poor probe 90 
variance (BAF-SD>0.063). These additional steps were performed to ensure that potential de 91 
novo CNVs would be of high quality, while being conservative and not removing a whole trio 92 
based on reduced data quality in just one parent. N=305 complete trios passed all of the above 93 
QC and were kept for analyses. After these steps, only CNVs of size >200kb were retained for 94 
analysis, to ensure accuracy of calls.  95 
CNVs were then annotated as ‘transmitted’, ‘non-transmitted’, or ‘likely de novo’ based on 96 
presence or absence of a call made in either parent and/or proband. All CNVs that were flagged 97 
as likely de novo were visually examined in the offspring and both confirmed biological parents 98 
and only clear-cut, un-ambiguous de novo calls were retained for analyses, minimising the false 99 
positive rate at the expense of potentially missing real calls. We did not perform validation, as 100 
the traces were definitive (see Supplementary Figures 1A-G). 101 
We examined whether the loci disrupted by the de novo CNVs had previously been implicated 102 
in case-control common variant2 and rare CNV studies4–6 of ADHD. Next we compared the 103 
list of de novo loci with rare CNV loci implicated in other neurodevelopmental disorders, using 104 
previously published studies of ASD8, DD/ID20, schizophrenia21,22, and Tourette disorder14. 105 
We also annotated each de novo CNV locus with genes and examined if any of these genes 106 
have been implicated in ASD, ADHD or DD/ID, based on studies of loss-of-function exonic 107 
mutations and deleterious missense variation3,9,23. A number of regions and genes overlapped 108 
across disorders. The merged lists of neurodevelopmental genetic risks consisted of 96 unique 109 
CNV loci and 197 unique genes. All loci were converted to genome build hg19. Overlap was 110 
defined as a CNV overlapping at least 50% of a previously implicated region or a CNV 111 
affecting the coding sequence of a gene in the list of genes of interest. 112 
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Results 113 
In the N=305 trios (of which, 36 or 11.8% were female probands) that passed QC, we detected 114 
a total of 14 de novo CNVs (N=9 that were >500kb and N=5 that were between 200-500kb) in 115 
13 ADHD probands, with one individual having two CNVs that were >500kb. Two of the de 116 
novo CNV carriers were female and the rest were male. The overall mutation rate was 4.6% 117 
(14/305) and the per individual rate was 4.3% (13/305). Although we did not have population 118 
controls available in this study, a recent study of control trios using similar methodology 119 
reported a de novo mutation rate of 1.0% for CNVs>200kb24; thus the rate in ADHD was over 120 
four times higher than this comparable control rate. The mutation rate of de novo deletions was 121 
3.3% and the rate of de novo duplications was 1.3%.  122 
The mean IQ of de novo CNV carriers was 83.6 (SD=13.0) and the mean IQ of the rest of the 123 
sample was 85.2 (SD=13.5), with 3 (25.0%) of the de novo CNV carriers (with non-missing 124 
IQ) having comorbid intellectual disability (ID; IQ<70), and 26 (9.6%) of the rest of the sample 125 
having comorbid ID. The group of de novo CNV carriers was too small to perform a statistical 126 
comparison. Information on age of the parents at birth of their children was available for only 127 
10 of the de novo CNV carriers [maternal age mean(SD) = 24.5(3.4); paternal age mean(SD) 128 
= 27.1(5.8)] and the means of the rest of the samples were: maternal age mean(SD) = 26.9(5.8); 129 
paternal age mean(SD) = 29.8(6.8). As with IQ, the sample was too small for a robust statistical 130 
comparison.  131 
Table 1 summarises the identified CNVs, annotated with affected genes. None of these genes 132 
overlapped with genes implicated by a recent ADHD genome-wide association study (GWAS)2 133 
or the list of genes implicated by recent sequencing studies of ASD, ADHD, and DD/ID3,9,23. 134 
However, four of the de novo CNVs have previously been robustly implicated in other 135 
neurodevelopmental disorders8,14,20–22, two of which have also been implicated previously in 136 
case-control CNV studies of ADHD4–6, as summarised in Table 2. In addition, duplications at 137 
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16p13.1125 and a de novo duplication at 15q13.126 have also previously been observed in 138 
people with schizophrenia. Given that a proportion of the current sample have previously been 139 
included in published case-control CNV studies4,5, we determined that eight of the de novo loci 140 
in our study overlap at least partially (≥50% overlap) with a previously reported CNV in a 141 
person with ADHD, with six of these eight de novo CNV carriers having taken part in the 142 
previous case-control studies. On the other hand, six of the loci in our study (4p16.3, 10q11.22-143 
q11.23, 10q21.3, 10q22.2, 15q26.3, and 16p13.3) are in novel regions and have not been 144 
previously reported in individuals diagnosed with ADHD in these large case-control studies. 145 
Of the samples included in previously published studies4,5, 6 were de novo CNV carriers, giving 146 
a de novo CNV rate of 4.4%. Of the samples not previously published, 6 were de novo CNV 147 
carriers, giving a comparable de novo CNV rate of 4.1%. 148 
Discussion 149 
In this study, we present observations on de novo CNVs from the largest published trio-based 150 
study of ADHD to date. The overall mutation rate for de novo CNV carriers was 4.6%, which 151 
is a similar rate to that observed for two other DSM-5 childhood neurodevelopmental disorders: 152 
ASD and Tourette disorder13,14, and somewhat higher than observed for schizophrenia7. 153 
Notably, the rate we observed is substantially higher than that which has been reported for 154 
controls24 and the previous and only trio-based study of ADHD that observed an overall rate 155 
of 1.7%16. Aside from the lower power of this previous, smaller study, one potential 156 
explanation for the difference is that, unlike Lionel and colleagues16, we did not exclude those 157 
with an IQ<70. However, in the current study, only three of the 13 individuals who were 158 
carrying de novo CNVs had an estimated IQ<70, with one further individual who had missing 159 
IQ data. The de novo CNV rate in children with ADHD without ID (IQ>70) was 3.5% in our 160 
study, compared to the 1.7% rate previously observed16.  161 
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The identified CNVs affected a total of 262 genes. None of the genes spanned by the de novo 162 
CNVs have been highlighted by the only exome sequencing study of ADHD to date3 or 163 
implicated in ADHD based on a recent, large case-control GWAS2. However, several of the 164 
CNVs have been implicated by previously published ADHD case-control CNV association 165 
studies (which will include inherited and de novo CNVs); these include the robustly implicated 166 
16p13.11 duplication and the 22q11.2 duplication4–6.  167 
The overlap of de novo CNV loci in the regions 15q13.1-13.2, 16p13.11, 16p12.2 and 22q11.21 168 
with loci previously implicated in ASD, DD/ID, Tourette disorder and schizophrenia is 169 
consistent with the notion that neuropsychiatric CNVs often have associations with a broad 170 
range of neurodevelopmental and psychiatric phenotypes27. Similar findings have emerged 171 
from the one sequencing study of ADHD, which highlighted strong overlap in the genes 172 
implicated in ADHD and ASD3, while GWAS demonstrate a moderate (rg=0.36) genetic 173 
correlation between ADHD and ASD28, and a previous CNV study suggested that the same 174 
biological pathways are impacted by CNVs in ADHD and ASD29. Our study adds to the 175 
growing body of literature supporting the relatively recent reconceptualization of ADHD as a 176 
neurodevelopmental disorder, as evidenced by its DSM-5 definition. 177 
However while there is overlap in implicated CNV regions (see Table 2), the type of CNV is 178 
usually but not always the same. In particular, we observed a de novo 22q11 duplication and 179 
although such duplications have been observed to be associated with risk of other 180 
neurodevelopmental disorders, they are protective for schizophrenia22, while deletions at this 181 
locus (not observed here) are associated with schizophrenia as well as other 182 
neurodevelopmental impairments21.  183 
One potential limitation of the study is that the proband DNA was more likely to come from 184 
saliva than blood (68.6% samples), whereas the parental DNA samples were more likely to 185 
come from blood (28.7% samples from saliva in mothers and 44.2% in fathers). Although the 186 
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QC metrics were somewhat poorer for the saliva samples, given the careful QC protocol and 187 
examination of all the traces (which were definitive; see Supplement), the rate of de novo CNVs 188 
in this study is unlikely to be overstated. Collecting blood samples from children with severe 189 
neurodevelopmental disorders poses a challenge for genetic research studies. Furthermore, 190 
although the comparison of the results of this study to previously published studies is limited 191 
by such differences in source of DNA, different genotyping arrays and variable CNV-calling 192 
protocols, our focus on well-defined large, rare CNV loci is a robust approach that is unlikely 193 
to be biased towards detecting false positives but may have resulted in missing valid de novo 194 
CNVs in the sample. 195 
Although ADHD is highly heritable, complex and polygenic, rare mutation discovery has been 196 
slower than for many other similarly heritable and polygenic disorders that include DD/ID, 197 
schizophrenia, ASD and Tourette disorder. For example, de novo CNV data are currently only 198 
available for around a total of 500 trios (Lionel and colleagues16 and the current study) and 199 
there have been no large, trio-based sequencing studies of ADHD. To identify associated 200 
variants, as well as damaging and likely causal rare mutations, will require very large sample 201 
sizes of ADHD that are not yet globally available. 202 
In summary, we present findings which suggest that de novo CNVs likely contribute to ADHD 203 
risk and highlight the need for larger discovery studies for future biological insights. 204 
 205 
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Table 1: A summary of the identified de novo CNVs 289 
Chr Start End Locus Type 
PennCNV 
score 
No. of 
probes 
Size 
No. 
genes 
hit 
Genes 
4 71566 1818625 4p16.3 DEL 234.044 654 1747059 36 
ZNF595, ZNF718, ZNF876P, ZNF732, ZNF141, ABCA11P, ZNF721, 
PIGG, PDE6B, ATP5I, MYL5, MFSD7, PCGF3, LOC100129917, CPLX1, 
GAK, TMEM175, DGKQ, SLC26A1, IDUA, FGFRL1, RNF212, TMED11P, 
SPON2, LOC100130872, CTBP1, CTBP1-AS1, MAEA, UVSSA, CRIPAK, 
FAM53A, SLBP, TMEM129, TACC3, FGFR3, LETM1 
4* 66110165 66881057 4q13.1-13.2 DEL 379.845 123 770892 2 EPHA5, LOC100144602 
4* 89020503 90256211 4q22.1 DUP 547.522 352 1235708 11 
ABCG2, PPM1K, HERC6, HERC5, PIGY, HERC3, NAP1L5, FAM13A-AS1, 
FAM13A, TIGD2, GPRIN3 
10 48302618 51832220 
10q11.22-
11.23 
DEL 1076.37 738 3529602 42 
ZNF488, RBP3, GDF2, GDF10, PTPN20A, PTPN20B, FRMPD2P1, 
BMS1P1, BMS1P5, GLUD1P7, FAM25B, FAM25C, FAM25G, 
LOC399753, FRMPD2, MAPK8, ARHGAP22, WDFY4, LRRC18, 
MIR4294, VSTM4, LOC100506733, FAM170B, C10orf128, C10orf71, 
DRGX, ERCC6, PGBD3, CHAT, SLC18A3, C10orf53, OGDHL, PARG, 
AGAP8, LOC728407, AGAP7, MSMB, NCOA4, TIMM23, AGAP6, 
FLJ31813, FAM21A 
10 68626126 68875634 10q21.3 DEL 110.26 39 249508 1 LRRTM3 
10 75940906 76360232 10q22.2 DEL 19.325 22 419326 1 ADK 
11 5653807 7482226 11p15.4 DEL 817.108 1198 1828419 52 
TRIM34, TRIM6-TRIM34, TRIM5, TRIM22, OR56B1, OR52N4, OR52N5, 
OR52N1, OR52N2, OR52E6, OR52E8, OR52E4, OR56A3, OR56A5, 
OR52L1, OR56A4, OR56A1, OR56B4, OR52B2, OR52W1, C11orf42, 
FAM160A2, CNGA4, CCKBR, PRKCDBP, SMPD1, APBB1, HPX, TRIM3, 
ARFIP2, FXC1, DNHD1, RRP8, ILK, TAF10, TPP1, DCHS1, MRPL17, 
GVINP1, OR2AG2, OR2AG1, OR6A2, OR10A5, OR10A2, OR10A4, 
OR2D2, OR2D3, ZNF215, ZNF214, NLRP14, RBMXL2, SYT9 
15 28962131 30369914 
15q13.1-
13.2 
DUP 295.843 234 1407783 8 
WHAMMP2, LOC100289656, LOC646278, GOLGA6L7P, APBA2, 
FAM189A1, NDNL2, TJP1 
15** 102165387 102398631 15q26.3 DEL 188.834 87 233244 5 TM2D3, TARSL2, OR4F6, OR4F15, OR4F13P 
16 6186577 6462231 16p13.3 DEL 186.718 50 275654 1 RBFOX1 
16 15493046 16251647 16p13.11 DUP 85.574 266 758601 9 
MPV17L, C16orf45, KIAA0430, NDE1, MIR484, MYH11, FOPNL, 
ABCC1, ABCC6 
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16 21966869 22392905 16p12.2 DEL 181.716 144 426036 7 UQCRC2, PDZD9, C16orf52, VWA3A, EEF2K, POLR3E, CDR2 
20 3090124 3891896 20p13 DEL 1115.83 407 801772 20 
UBOX5, UBOX5-AS1, FASTKD5, PROSAPIP1, DDRGK1, ITPA, SLC4A11, 
C20orf194, ATRN, GFRA4, ADAM33, SIGLEC1, HSPA12B, C20orf27, 
SPEF1, CENPB, CDC25B, AP5S1, MAVS, PANK2 
22 18892575 21460220 22q11.21 DUP 129.788 824 2567645 67 
DGCR6, PRODH, DGCR5, DGCR9, DGCR10, DGCR2, DGCR11, DGCR14, 
TSSK2, GSC2, SLC25A1, CLTCL1, HIRA, MRPL40, C22orf39, UFD1L, 
CDC45, CLDN5, LOC150185, Sep-05, SEPT5-GP1BB, GP1BB, TBX1, 
GNB1L, C22orf29, TXNRD2, COMT, MIR4761, ARVCF, C22orf25, 
MIR185, DGCR8, MIR3618, MIR1306, TRMT2A, RANBP1, ZDHHC8, 
LOC388849, LOC284865, LOC150197, RTN4R, MIR1286, DGCR6L, 
LOC729444, TMEM191B, PI4KAP1, RIMBP3, ZNF74, SCARF2, KLHL22, 
MED15, POM121L4P, TMEM191A, PI4KA, SERPIND1, SNAP29, CRKL, 
AIFM3, LZTR1, THAP7, THAP7-AS1, TUBA3FP, P2RX6, SLC7A4, 
P2RX6P, LOC400891, BCRP2 
All coordinates are genome build hg19. 290 
* These 2 CNVs were located in the same individual; DEL: deletion; DUP: duplication. 291 
** This individual has been independently diagnosed with ring chromosome 15 by a clinical geneticist.292 
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Table 2: Identified de novo CNV regions that have previously been robustly implicated in 293 
ADHD and other neurodevelopmental disorders 294 
CNV 
CNV locus previously implicated in ADHD or another disorder 
ADHD ASD DD/ID SCZ TD 
15:28962131-30369914 (DUP)     DUP 
16:15493046-16251647 (DUP) DUP  DEL/DUP DUP  
16:21966869-22392905 (DEL)   DEL DEL  
22:18892575-21460220 (DUP) DEL/DUP DEL/DUP DEL/DUP DEL DUP 
ASD: autism spectrum disorder; DD/ID: developmental delay/intellectual disability; SCZ: 295 
schizophrenia; TD: Tourette disorder 296 
